Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Experiences of case managers in providing. , & Reijneveld, S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Planning of radiotherapy capacity and productivity. Kumar,. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. (). SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kim, & Blakeney, ). MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. Radiother. SLOTMAN BJ, VOS PH. ; (2), KIM MS et al. Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. . Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective.